Lighthouse Guild, New York, New York.
Department of Ophthalmology, Columbia University, New York, New York.
JAMA Ophthalmol. 2019 Jun 1;137(6):634-640. doi: 10.1001/jamaophthalmol.2019.0446.
Patients with vision loss who are hospitalized for common illnesses are often not identified as requiring special attention. This perception, however, may affect the outcomes, resource use, and costs for these individuals.
To assess whether the mean hospitalization lengths of stay, readmission rates, and costs of hospitalization differed between individuals with vision loss and those without when they are hospitalized for similar medical conditions.
DESIGN, SETTING, AND PARTICIPANTS: This analysis of health care claims data used 2 sources: Medicare database and Clinformatics DataMart. Individuals with vision loss were matched 1:1 to those with no vision loss (NVL), on the basis of age, years from initial hospitalization, sex, race/ethnicity, urbanicity of residence, and overall health. Both groups had the same health insurance (Medicare or a commercial health plan), and all had been hospitalized for common illnesses. Vision loss was categorized as either partial vision loss (PVL) or severe vision loss (SVL). Data were analyzed from April 2015 through April 2018.
The outcomes were lengths of stay, readmission rates, and health care costs during hospitalization and 90 days after discharge. Multivariable logistic and linear regression models were built to identify factors associated with these outcomes among the NVL, PVL, and SVL groups.
Among Medicare beneficiaries, 6165 individuals with NVL (with a mean [SD] age of 82.0 [8.3] years, and 3833 [62.2%] of whom were female) were matched to 6165 with vision loss. Of those with vision loss, 3401 (55.2%) had PVL and 2764 (44.8%) had SVL. In the Clinformatics DataMart database, 5929 individuals with NVL (with a mean [SD] age of 73.7 [15.1] years, and 3587 [60.5%] of whom were female) were matched to 5929 individuals with vision loss. Of the commercially insured enrollees with vision loss, 3515 (59.3%) had PVL and 2414 (40.7%) had SVL. Medicare enrollees with SVL, compared with those with NVL, had longer mean lengths of stay (6.48 vs 5.26 days), higher readmission rates (23.1% vs 18.7%), and higher hospitalization and 90-day postdischarge costs ($64 711 vs $61 060). Compared with those with NVL, Medicare beneficiaries with SVL had 4% longer length of stay (estimated ratio, 1.04; 95% CI, 1.01-1.07; P = .02), 22% higher odds of readmission (odds ratio, 1.22; 95% CI, 1.06-1.41; P = .007), and 12% higher costs (estimated cost ratio, 1.12; 95% CI, 1.06-1.18; P < .001). Similar findings were obtained for those with commercial health insurance. When these findings were extrapolated to hospitalizations of patients with vision loss nationwide, an estimated amount of more than $500 million in additional costs annually were spent caring for these patients.
These findings suggest that opportunities for improving outcomes and reducing costs exist in addressing patients' vision loss and concomitant functional difficulties during hospitalization and thereafter.
因常见疾病住院的视力丧失患者通常未被认为需要特殊关注。然而,这种看法可能会影响这些患者的预后、资源使用和住院费用。
评估在因相似医疗条件住院时,视力丧失患者与无视力丧失患者(NVL)的平均住院时间、再入院率和住院费用是否存在差异。
设计、地点和参与者:本项基于医疗保险数据库和 Clinformatics DataMart 这 2 个数据源的卫生保健索赔数据分析使用了匹配方法。基于年龄、初次住院后年限、性别、种族/民族、居住地城市度和整体健康状况,将视力丧失患者与 NVL 患者 1:1 匹配。两组均具有相同的医疗保险(医疗保险或商业健康计划),且所有患者均因常见疾病住院。视力丧失分为部分视力丧失(PVL)或严重视力丧失(SVL)。数据分析时间为 2015 年 4 月至 2018 年 4 月。
结局是住院和出院后 90 天的住院时间、再入院率和医疗保健费用。使用多变量逻辑和线性回归模型,确定 NVL、PVL 和 SVL 组中与这些结局相关的因素。
在医疗保险受益人群中,6165 名 NVL(平均[标准差]年龄为 82.0[8.3]岁,其中 3833 名[62.2%]为女性)与 6165 名视力丧失患者相匹配。在有视力丧失的患者中,3401 名(55.2%)患有 PVL,2764 名(44.8%)患有 SVL。在 Clinformatics DataMart 数据库中,5929 名 NVL(平均[标准差]年龄为 73.7[15.1]岁,其中 3587 名[60.5%]为女性)与 5929 名视力丧失患者相匹配。在商业保险中,3515 名视力丧失患者(59.3%)患有 PVL,2414 名(40.7%)患有 SVL。与 NVL 相比,SVL 患者的平均住院时间更长(6.48 天 vs 5.26 天)、再入院率更高(23.1% vs 18.7%)、住院和 90 天出院后费用更高(64711 美元 vs 61060 美元)。与 NVL 相比,SVL 医疗保险受益人的住院时间延长了 4%(估计比值,1.04;95%CI,1.01-1.07;P=.02)、再入院的可能性高 22%(比值比,1.22;95%CI,1.06-1.41;P=.007)、费用高 12%(估计费用比值,1.12;95%CI,1.06-1.18;P<.001)。在具有商业健康保险的患者中也发现了类似的结果。当将这些发现外推至全国视力丧失患者的住院治疗时,估计每年为这些患者的护理多花费 5 亿多美元。
这些发现表明,在处理患者住院期间的视力丧失及其伴随的功能障碍方面,存在改善预后和降低成本的机会。